Arvinder Dhalla

Arvinder joined InCube labs in 2016 with more than 15 years of experience in pharmaceutical research & development, project management, and regulatory submissions across several therapeutic areas including, cardiovascular, metabolic diseases, and PAH. Previously, Arvinder was Director of Biology in the Cardiovascular Therapeutic Area at Gilead Sciences from 2009-2015 where she led multiple drug development programs from early discovery to clinical development. Arvinder led several programs as a scientist and senior scientist from 2001-2008 at CV Therapeutics which was acquired by Gilead Sciences. Arvinder holds several patents and has authored 50 scientific papers. Arvinder holds a BS and MS in Biophysics from Panjab University, India, and a Ph.D. in Physiology from the University of Manitoba, Canada.